Anzeige
Mehr »
Mittwoch, 02.07.2025 - Börsentäglich über 12.000 News
Nach dem Genius Act: Dieses börsennotierte XRP-Unternehmen greift im Token-Finanzmarkt an!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
457 Leser
Artikel bewerten:
(1)

GreenLight Biosciences Partners With Fraunhofer IME To Accelerate Eco-Friendly Crop Protection Using RNA

Partnership to study use of RNA to protect crops, protect bees and support biodiversity in new collaboration between famed German applied research institute and cutting edge RNA biotech.

BOSTON and GIESSEN, Germany, March 29, 2021 /PRNewswire/ -- GreenLight Biosciences will work with the Fraunhofer Institute for Molecular Biology and Applied Ecology IME to research new and promising RNA-based advances for environmentally-friendly food production for a growing global population.

While crop protection uses a different type of RNA from Covid vaccines, GreenLight's proprietary platform allows for the large scale production of RNA for human health, animal health and plant health. The collaboration with Fraunhofer IME aims to help GreenLight Biosciences create advances that protect crops around the world while ensuring biodiversity.

Fraunhofer IME will provide access to scientific experts and state-of-the art laboratory resources to boost GreenLight Biosciences' research and development capabilities. Founded in 1949 to advance commercial application of basic science, Fraunhofer is known for a wide range of innovations with global impact, ranging from the MP3 standard for music compression to solar panels of world record breaking efficiency.

GreenLight Biosciences is developing new crop protections that draw on scientific advances underpinning large scale production of RNA Covid vaccines. These solutions will enable farmers to grow crops without harming beneficial insects like bees, while being safe for people, soil and water. RNA-based products only target the insect that they are designed to control and break down rapidly.

This collaborative effort will focus on identifying new sustainable RNA alternatives to petroleum-based chemical pesticides. Among the first products to be trialled will be GreenLight's RNA solution to protect potatoes from the Colorado Potato Beetle.

Fraunhofer IME offers advanced biological assays and bioinformatic tools that can be used to quickly identify pest targets, develop new bioactive molecules, and validate their efficacy on crops. The research will be conducted in Giessen, Germany.

"RNA biologics is an exciting field that holds great potential for allowing farmers to deliver sustainable, environmentally-safe products to give consumers the cleaner, greener products they demand," said Prof. Dr. Andreas Vilcinskas, who heads the branch for bioresources at Fraunhofer IME. "We are teaming up with GreenLight Biosciences to help the world gain greater food security with more sustainable and eco-friendly agriculture."

"Finding ways to farm without harming bees and without damaging biodiversity is one of humanity's biggest challenges," said Dr. Andrey Zarur, CEO of GreenLight Biosciences. "To tackle this we are joining forces with one of the world's most experienced research institutes in a country long-dedicated to sustainable agriculture."

About the Fraunhofer Institute for Molecular Biology and Applied Ecology IME
The Fraunhofer Institute for Molecular Biology and Applied Ecology IME, with over 400 employees at its four sites in Schmallenberg, Aachen, Giessen and Münster, conducts research in the field of applied life sciences from a molecular level to entire ecosystems, in the areas of pharmacy, medicine, chemistry, agriculture, as well as environmental and consumer protection. Our mission is the development and use of advanced technologies for the protection of crop plants and food sources. For more information, visit: https://www.ime.fraunhofer.de/en.html

About GreenLight Biosciences, Inc.
GreenLight Biosciences is an integrated life sciences company with a cutting-edge platform that can deliver high-quality RNA more quickly and less expensively than previously possible. GreenLight develops RNA products and collaborates with industry leaders to advance human vaccine and therapy development, pandemic preparation, crop management, plant protection and support the health of bees and other pollinators. The GreenLight team values diversity, inclusion, and equality and promises to use collaboration to remain scientifically imaginative and passionately focused on making a difference in the world. For more information, visit https://www.greenlightbiosciences.com/

© 2021 PR Newswire
Zeitenwende! 3 Uranaktien vor der Neubewertung
Ende Mai leitete US-Präsident Donald Trump mit der Unterzeichnung mehrerer Dekrete eine weitreichende Wende in der amerikanischen Energiepolitik ein. Im Fokus: der beschleunigte Ausbau der Kernenergie.

Mit einem umfassenden Maßnahmenpaket sollen Genehmigungsprozesse reformiert, kleinere Reaktoren gefördert und der Anteil von Atomstrom in den USA massiv gesteigert werden. Auslöser ist der explodierende Energiebedarf durch KI-Rechenzentren, der eine stabile, CO₂-arme Grundlastversorgung zwingend notwendig macht.

In unserem kostenlosen Spezialreport erfahren Sie, welche 3 Unternehmen jetzt im Zentrum dieser energiepolitischen Neuausrichtung stehen, und wer vom kommenden Boom der Nuklearindustrie besonders profitieren könnte.

Holen Sie sich den neuesten Report! Verpassen Sie nicht, welche Aktien besonders von der Energiewende in den USA profitieren dürften, und laden Sie sich das Gratis-PDF jetzt kostenlos herunter.

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.